<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19"^^ . "Aim. The objective of this study was to evaluate sedation therapy effectiveness in critically ill patients with severe COVID-19 who received dexmedetomidine compared to propofol. Methods. The research was done in a prospective single center to a cohort study of critically ill 333 adult patients with COVID-19 and psychoemotional disorders (depression, anxiety and posttraumatic stress disorder) admitted in the ICU of the Republican Specialized Hospital for COVID-19 in Uzbekistan. Patients were non-invasive ventilated more than 24 hours and received intravenous sedation with dexmedetomidine or propofol. Results. The risk of progression of the pathological process decreased from 47.6% to 21.8% and, accordingly, the proportion of patients with stabilization and improvement of their condition increased from 52.4% to 79.4% (p<0.001). The possibilities of non-invasive respiratory support were expanded with a reduction in the frequency of tracheal intubations from 17.3% to 7.3% (p<0.001), the duration of ICU stay was from 12.6±0.8 to 9.4±0.6 days, and the duration of respiratory therapy was from 8.4±0.5 to 5.2±0.4 days. In particular, there was an improvement in oxygen saturation (SpO2) recovery after one day of intensive therapy from 86.6±0.2% to 92.2±0.3% with non-invasive ventilation and a higher oxygenation index (2.3 in the dexmedetomidine group versus 1.6 in the propofol group, p=0.032) during the period of sedation withdrawal. Conclusion. In the presence of severe psychoemotional disorders, the effectiveness of etiotropic and pathogenetic treatment protocols of COVID-19 directly depends on the proper sedation regimen. In this aspect, dexmedetomidine provides adequate and safe respiratory support with an improvement in external respiration, blood gas composition and a minimal negative hemodynamic effect."^^ . "2021-09-25" . . "11" . "05" . . "Scienceline Publications, Ltd"^^ . . . "Journal of Life Science and Biomedicine"^^ . . . "22519939" . . . . . . . . . . . . . . . . "Begali Bobokulovich"^^ . "KHAKIMOV"^^ . "Begali Bobokulovich KHAKIMOV"^^ . . "Ravshan Aliyevich"^^ . "IBADOV"^^ . "Ravshan Aliyevich IBADOV"^^ . . "Sardor Khamdamovich"^^ . "IBRAGIMOV"^^ . "Sardor Khamdamovich IBRAGIMOV"^^ . . "Anvar Shamkhatovich"^^ . "ARIFJANOV"^^ . "Anvar Shamkhatovich ARIFJANOV"^^ . . . . . . "Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19 (Text)"^^ . . . . . "JLSB 11(5) 80-87, 2021-Dexmedetomidine for psychoemotional disorders in COVID-19 patients.pdf"^^ . . . "Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19 (Other)"^^ . . . . . . "indexcodes.txt"^^ . . "HTML Summary of #570 \n\n\n \n Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19\n \n\n" . "text/html" . . . "Q Science (General)"@en . . . "R Medicine (General)"@en . .